Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reolysin with FOLFOX6 and Bevacizumab in Metastatic Colorectal Cancer
NCT01622543Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2012
- Primary completion
- Jan 2017
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pelareorep in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Progression Free Survival at 19 months. Started Oct 2012; status: completed.
02
Drugs
pelareorep
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01622543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622543.